NCT06184503View on ClinicalTrials.gov

Analysis of Velmanase Alfa (Lamzede®)'s Effects in the Body of Children With Alpha-Mannosidosis Under the Age 3

RecruitingOBSERVATIONAL
Enrollment

5

Participants

Timeline

Start Date

February 19, 2025

Primary Completion Date

September 30, 2029

Study Completion Date

September 30, 2029

Conditions
Alpha-Mannosidosis
Interventions
DRUG

Velmanase Alfa

Lamzede® (velmanase alfa, henceforth referred to as Lamzede) is a recombinant human lysosomal alpha-mannosidase product developed as an intravenous enzyme replacement therapy (ERT) for the treatment of alpha-mannosidosis.

Trial Locations (2)

29605

RECRUITING

Greenwood Genetic Center, Greenwood

33155

RECRUITING

Nicklaus Children's Hospital, Miami

All Listed Sponsors
lead

Chiesi Farmaceutici S.p.A.

INDUSTRY